Loading quotes...

Forecast

Buy	6
Hold	4
Sell	2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Genmab doubles after three Phase 3 wins as it shifts to owning more medicines

Genmab's shares have doubled in three months following three positive Phase 3 cancer trial results in October, including petosemtamab combined with Keytruda which halved the risk of death in recurrent or metastatic head and neck cancer. The Danish biotech is using royalty income from drugs like Darzalex to fund acquisitions and keep larger commercial stakes in drugs it develops, having fully acquired petosemtamab and Rina-S and co-commercialized Epkinly with AbbVie. Management expects petosemtamab to be a multi-billion-dollar asset and is expanding commercial infrastructure to sell majority-owned medicines directly, while acknowledging higher costs and market risks. Genmab will report third-quarter earnings on Nov. 5. » More on cnbc.com
Genmab achieves positive study data on petosemtamab and reaches new all-time high

Genmab presented data on petosemtamab that show clinical success in head‑and‑neck tumors and underscore the quality of its own research. Stable revenues from the multiple myeloma drug Darzalex enable the company to expand independent oncology commercialization. The progress contributed to a fresh all‑time high for the stock. » More on finanzen.net
Genmab achieves positive phase‑3 data for petosemtamab and stock rises 25 percent

The phase‑3 LiGeR‑HN1 study shows that petosemtamab in combination with pembrolizumab met both primary endpoints in PD‑L1‑positive head and neck squamous cell carcinoma and reduced the risk of death by 50 percent. Genmab now plans to begin talks with global regulators and to present detailed results at a scientific conference. The news propelled the stock up about 25 percent and for now eases concerns about revenue risks following the Darzalex patent expiry. » More on deraktionaer.de
Genmab: positive Phase‑2 data on petosemtamab in metastatic colorectal cancer

Petosemtamab showed response rates of 75% in first-line and 67% in second-line metastatic colorectal cancer in Phase‑2 combination studies with standard chemotherapies. The safety profile was solid, with treatment-related discontinuation rates of 3–5% and no treatment-related deaths. The mature data support the global Phase‑3 program and underscore the commercial potential of the bispecific agent. » More on finanzen.net
Genmab rises to multi‑year high after study data and signals further upside potential

Genmab climbs to a multi‑year high following positive study data, generating a fresh buy signal for trend followers. Analysts note that expanding the patient population for Epcoritamab could give the company blockbuster potential. License payments for Darzalex provide a financial cushion that supports clinical development from the company’s own cash flow and could enable further share-price gains. » More on finanzen.net

Financials

In the last quarter, Genmab had revenue of €1.05bn and net profit of €301.93m

(EUR)	September 2026	YoY
Revenue	1.05bn	81.16%
Gross profit	970.25m	18.11%
Net profit	301.93m	11.64%
EBITDA	434.36m	1.34%

Fundamentals

Metric	Value
Market capitalization	€28.36bn
Number of shares	61.49m
52-week high/low	€527.92 - €202.23
Dividends	No
Beta	0.65
P/E ratio	42.84
PEG ratio	-0.51
P/B ratio	4.93
P/S ratio	7.27

Company profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.